A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers
Latest Information Update: 06 Dec 2024
At a glance
- Drugs LMN 101 (Primary)
- Indications Campylobacter infections; Traveller's diarrhoea
- Focus Adverse reactions
- Sponsors Lumen Bioscience
Most Recent Events
- 03 Jul 2020 Status changed from active, no longer recruiting to completed.
- 26 May 2020 Planned End Date changed from 1 Jun 2020 to 24 Jun 2020.
- 26 May 2020 Status changed from not yet recruiting to active, no longer recruiting.